We assayed changes in BCL2 expression following I-BET726 treatment in a number of neuroblastoma cell lines and observed potent and concentration-dependent suppression of BCL2 in every cell line tested (Figure 6A). The gene discussed is BCL2; the disease is neuroblastoma.